Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7391100 | 1.00 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3195920 | 1.00 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30670318 | 1.00 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29400419 | 1.00 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30055820 | 1.00 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29511466 | 1.00 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL23463315 | 0.91 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL23623229 | 0.88 | CASP3 (0.53) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL557482 | 0.87 | KMT2A (0.58) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3201847 | 0.87 | CASP3 (0.61) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-115702026-A | Macrocyclic compounds and methods of use thereof | 基因泰克公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| CN-101511783-A | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions | NOVARTIS AG (CH) | 2009-08-19 | — | — | CN | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885KMT2A 4608/4885MDM4 3559/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | CASP3 2910/4885KMT2A 1219/4885MDM4 1166/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CASP3 343/4885KMT2A 4608/4885MDM4 3559/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CASP3 343/4885KMT2A 4608/4885MDM4 3559/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CASP3 343/4885KMT2A 4608/4885MDM4 3559/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885KMT2A 4608/4885MDM4 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.